MYLUNG Consortium Study Protocol 2
This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Checked against the public recordLast updated May 18, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- US Oncology Research
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer * Eligible for systemic therapy based on the treating provider's assessment * Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease * Subjects may be enrolled within 30 days of initiation of systemic therapy * Signed informed consent Exclusion Criteria: * Stage IA at the time of enrollment * Subjects with small cell lung cancer * Subjects with Unknown primary tumor origin
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Southern Cancer Center, PCDaphne, Alabama
- Rocky Mountain Cancer CenterDenver, Colorado
- Woodlands Medical Specialists, PAPensacola, Florida
- Illinois Cancer SpecialistsNiles, Illinois
- Maryland Oncology Hematology, P.A.Silver Spring, Maryland
- Minnesota Oncology Hematology, P.A.Minneapolis, Minnesota
- New York Oncology Hematology, P.C.Albany, New York
- Oncology Hematology Care Clinical Trials, LLCCincinnati, Ohio
- Willamette Valley Cancer Institute and Research CenterEugene, Oregon
- Texas Oncology - West TexasAbilene, Texas
- Texas Oncology- DFWWArlington, Texas
- Texas Oncology-Dallas Presbyterian HospitalDallas, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 18, 2026. Always confirm current availability with the study team.